- Report
- September 2025
- 250 Pages
Global
From €3994EUR$4,490USD£3,470GBP
- Report
- March 2025
- 173 Pages
Global
From €4003EUR$4,500USD£3,478GBP
- Report
- April 2025
- 175 Pages
Global
From €3994EUR$4,490USD£3,470GBP
- Report
- August 2025
- 150 Pages
Global
From €2987EUR$3,358USD£2,595GBP
€3514EUR$3,950USD£3,053GBP
- Report
- August 2020
- 139 Pages
Global
From €2446EUR$2,750USD£2,125GBP
- Report
- November 2019
- 167 Pages
Global
From €2446EUR$2,750USD£2,125GBP
- Report
- June 2025
- 119 Pages
Thailand
From €2668EUR$2,999USD£2,318GBP
- Report
- July 2024
- 324 Pages
Europe
From €2446EUR$2,750USD£2,125GBP
- Report
- August 2023
- 58 Pages
Global
€1786EUR$2,078USD£1,499GBP
Synthetic Cannabinoids are a class of analgesic drugs that are designed to mimic the effects of cannabis. They are typically used to treat chronic pain, nausea, and other conditions. Synthetic Cannabinoids are often used in combination with other analgesics, such as opioids, to provide a more comprehensive approach to pain management. They are also used to treat conditions such as anxiety, depression, and insomnia. Synthetic Cannabinoids are generally considered to be safer than traditional cannabis products, as they are not associated with the same risks of addiction and abuse.
The Synthetic Cannabinoids market is growing rapidly, as more people are turning to these drugs to manage their pain and other conditions. The market is expected to continue to expand as more research is conducted into the potential benefits of these drugs.
Some of the major companies in the Synthetic Cannabinoids market include GW Pharmaceuticals, Insys Therapeutics, AbbVie, and Zynerba Pharmaceuticals. Show Less Read more